Immatics N.V. announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy across multiple solid tumor types. As of the August 7, 2026 data cutoff, 98 heavily pretreated patients across ...

The Bills exit their bye at 5-1 with Maxwell Hairston struggling outside and Greg Rousseau rushing alone, and Zay Flowers and ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today shared the first data from ...

Pittsburgh will take on the Saints in Week 7 — what can the Steelers expect from their Paris opponent?

Multiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P) , including patients with and without detectable baseline ...

OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC ...

Median OS was 10.2 months in the arcotatug tavatecan group versus 6.9 months with treatment of physician's choice, representing a 43% reduction in the risk of death (HR=0.57; P<0.0001). Median PFS, ...

Zai Lab reported an 81.8% response rate for zoci plus atezolizumab in a Phase 1b small cell lung cancer trial and plans a ...

Blackstone remains a strong buy as record AUM, massive inflows, and AI growth offset Q3 earnings weakness for a 2027 breakout ...

Faster and higher expansion of tumor-targeting CD8 T cells associated with longer overall survival in previously treated mismatch repair proficient (pMMR) metastatic ...

In December 2025, Johnson & Johnson completed its acquisition of Halda Therapeutics, adding JNJ-6143 and the RIPTAC platform to its oncology portfolio.

Enozertinib shows strong efficacy in advanced NSCLC with EGFR atypical mutations, entering Phase 3 trials in 2027. ORIC ...